Unfortunately, the text you’ve provided seems to be an introduction or a fragment and it doesn’t contain enough content to summarize into 800 words. The paragraph offers a brief overview of the FDA’s new draft guidance on diversity action plans, indicating that this guidance was completely rewritten following new authority granted to the FDA by Congress in 2022. This guidance aims to provide detailed recommendations to sponsors of drug and device programs on complying with new legal standards and clarifies aspects regarding the waiving of certain requirements. To provide a more detailed summary or further details, please provide the full article or additional content about the topic.
#FDA #published #Diversity #Action #Plan #guidance #Heres #Exclusive #Analysis #Life #Science
July 4, 2024
Artificial Intelligence
FDAcop
